Skip to content
Search

Latest Stories

India's badminton players urge extension of Olympic qualifying

Indian badminton star Saina Nehwal on Sunday (1) urged the sport's world body to extend its Olympic qualification period as the spread of the coronavirus forces the cancellation or postponement of competitions.

The German Open, which was to be held between March 3 and 8, has been cancelled while the China Masters and Polish Open have been postponed and dropped from the Olympic qualifying process.


The Badminton World Federation has refused to extend its qualification deadline from April 28 for the Tokyo Games, which kicks off in July.

Nearly 3,000 people have died and about 87,000 infected worldwide since the virus was first detected late last year in the central Chinese city of Wuhan.

"It will be unfair for most of the players who are really close to qualifying for Olympics 2020," Nehwal, the first Indian badminton player to win an Olympic medal with a bronze at the 2012 London Games, tweeted.

Her husband Parupalli Kashyap, who also represents India, said he was concerned that qualification events were being cut.

The loss of tournaments poses problems for many players including two-time Olympic champion Lin Dan, who needs a rapid rise up the rankings to win a place on the Chinese team.

"We all had seven events starting from Spain Masters until the Singapore Open and few have the Asian Champs too," Kashyap wrote on Twitter.

"It will be completely unfair for so many athletes who are on the borderline of qualification at this moment... I hope all the athletes have a fair chance to qualify for the Olympics."

The top 16 players who make it to the Tokyo Games will be decided through their performances at coming tournaments, including the All England Open (March 11-15) and the India Open (March 24-29).

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less